Sucralfate efficacy in gastroesophageal reflux disease
Pro Research Analysisby 
Searched over 200M research papers
Sucralfate Efficacy in Gastroesophageal Reflux Disease: Clinical Outcomes
Sucralfate in Non-Erosive Gastroesophageal Reflux Disease (NERD)
A randomized, double-blind, placebo-controlled study found that sucralfate gel significantly improved symptoms in patients with moderate to severe NERD. After six weeks, 71% of patients treated with sucralfate were classified as responders, compared to only 29% in the placebo group. Additionally, 45% of sucralfate-treated patients had a "good" or "excellent" overall response, versus 22% for placebo, with few adverse effects reported . This suggests that sucralfate gel is effective and well-tolerated in NERD.
Sucralfate in Erosive Reflux Esophagitis
Several studies have evaluated sucralfate in patients with erosive esophagitis. In a pilot study of patients with severe, refractory reflux esophagitis, sucralfate led to both symptomatic and endoscopic improvement, with complete healing observed in most patients after 4–6 months of uninterrupted therapy . Another open clinical trial showed that 12 weeks of sucralfate treatment significantly reduced reflux and eliminated esophageal mucosal damage in patients with esophagitis .
Comparison with H2-Receptor Antagonists
Multiple studies and a meta-analysis have compared sucralfate to H2-receptor antagonists (such as cimetidine and ranitidine). The results consistently show that sucralfate is as effective as H2-receptor antagonists in improving symptoms and healing esophagitis, with no significant differences in overall efficacy between the two treatments 467. Symptom relief and endoscopic healing rates were similar, making sucralfate a valid alternative for patients who cannot tolerate or do not respond to H2-receptor antagonists 467.
Sucralfate as Adjunctive Therapy
When used in combination with cimetidine, sucralfate provided additional improvement in daytime heartburn and endoscopic outcomes compared to cimetidine alone, although the difference in complete healing rates was not statistically significant . This suggests a possible benefit of combining sucralfate with acid-suppressing therapy in severe cases.
Sucralfate Formulations and Clinical Performance
The clinical performance of standard sucralfate (tablet or suspension) has been described as inconsistent and generally unimpressive for both erosive and non-erosive GERD, leading to its exclusion from most clinical guidelines. However, a mucoadherent gel formulation of sucralfate demonstrated superior efficacy in NERD, likely due to better retention on the esophageal mucosa . This highlights the importance of formulation in sucralfate’s effectiveness.
Sucralfate in Combination Therapy
A study evaluating triple therapy (mosapride, omeprazole, and sucralfate) found that adding sucralfate improved recovery and total effective rates compared to dual therapy (mosapride and omeprazole alone). The recurrence rate was also lower in the group receiving sucralfate, with no significant difference in adverse reactions . This suggests that sucralfate may enhance the efficacy of standard GERD treatments.
Placebo-Controlled Trials and Limitations
Some placebo-controlled trials did not find a statistically significant difference between sucralfate and placebo in symptom improvement or healing rates, though there was a trend toward better outcomes with sucralfate . Unequal distribution of disease severity in study groups may have influenced these results, and a potential benefit of sucralfate cannot be excluded .
Conclusion
Sucralfate is effective in improving symptoms and healing mucosal damage in both non-erosive and erosive forms of gastroesophageal reflux disease. Its efficacy is comparable to H2-receptor antagonists, and it may provide additional benefit when used in combination with other therapies. The formulation of sucralfate (such as mucoadherent gel) can influence its clinical effectiveness. While some studies show only modest benefits, sucralfate remains a safe and valid alternative, especially for patients who cannot use or do not respond to standard acid-suppressing medications 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Sucralfate gel versus placebo in patients with non‐erosive gastro‐ oesophageal reflux disease.
Sucralfate gel at 1g b.d. significantly improves symptoms of gastro-oesophageal reflux disease compared to placebo, with a 71% responder rate and well-tolerated treatment.
Effect of sucralfate on gastroesophageal reflux in esophagitis.
Sucralfate significantly reduces gastroesophageal reflux and eliminates esophageal mucosal damage in patients with esophagitis, potentially due to its barrier protecting properties.
Efficacy of Sucralfate in Reflux Disease in comparison to H2 – Receptor Antagonist: A Meta-Analysis of Randomized Trials
Sucralfate is an effective alternative for treating reflux disease, with no statistical significant difference between the two treatments.
DOI